Recruiting

Testing a new virus-based cancer treatment alone and with other drugs

Plain-English translation of NCT05076760 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated June 2026 · How we translate trials

What is this trial?

This study is testing MEM-288, an experimental cancer treatment made from a specially engineered virus that is designed to infect and destroy cancer cells while also activating your immune system to fight the cancer. The virus is injected directly into a tumor lesion that can be felt under the skin. Researchers want to understand whether this medication works better on its own or when combined with other standard cancer treatments like immunotherapy or chemotherapy.

Many patients with advanced cancers stop responding to standard immunotherapy drugs, leaving them with few treatment options. This trial is exploring whether this new virus-based treatment can help people whose cancers have become resistant to existing therapies by attacking cancer cells through a completely different mechanism.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with advanced or metastatic cancer (such as lung cancer, skin cancer, melanoma, breast cancer, pancreatic cancer, or head and neck cancer)
your cancer has progressed despite previous treatment with checkpoint inhibitor therapy (standard immunotherapy)
you have at least one tumor lesion that can be felt under the skin or in a lymph node and is large enough to receive an injection
you are in good enough overall health to participate in the study (ECOG performance status of 0 or 1)

You likely don't qualify if…

you have not received prior treatment with standard cancer therapies for your specific cancer type
your tumor lesions cannot be safely injected or are not accessible under the skin
you are unable to attend scheduled study visits every three weeks
you have severe organ dysfunction or other serious medical conditions that would make participation unsafe

What participation looks like

You will receive injections of the medication directly into a tumor under your skin, typically once every three weeks for a planned minimum of two doses (and up to a maximum of six doses). Depending on which part of the study you join, you may receive this medication alone or in combination with other standard cancer drugs given by IV infusion. Throughout the study, you will have regular visits for blood tests, imaging scans, and check-ups to monitor how your cancer is responding and to watch for any side effects.

Testing a new virus-based cancer treatment alone and with other drugs

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)